i2B Presentation

Inflammation - Immunopathology - Biotherapy
from rare to common diseases.

Prof. Serge Amselem &
Prof. David Klatzmann



WP1: Patient care, Cohorts, Deep phenotyping & Clinical trials.

WP2: Basic & Translational research.

WP3: Translational medicine and Biotherapy.



Teaching & dissemination

One of our main tasks is to propose a clear, coherent and open offer for teaching and disseminating knowledge/practice in the fields covered by the participants.

More ​​​

Clinical Trials

We have recognized expertise in the design & management of clinical trials (phase I - IV) in inflammatory & autoimmune diseases. This comprises several medical fields including internal medecine, rheumatology, gastroenterology, nephrology, pulmonology, ophthalmology and neurology.

Featured events

Launch Horizon 2020

With recognized expertise​ from bench to bedside in the field of inflammatory and autoimmune disorders, the i2B consortium is open to collaborations within the newly launched 2014-2015 workprogram​ of H2020, specially for the "Personalising​​ health and care" challenge. For ...

TRANSREG has been launched.

​TRANSREG ​​is a multicenter, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose IL2 across 11 selected autoimmune diseases (12 patients/disease) including heumatoid arthritis, ankylosing spondylitis, systemic lupus eryth...
Latest news

Lancement de l'essai MS-IL2

​​​​​​​MS-IL2 vient d'obtenir l'autorisation de l'ANSM pour étudier le potentiel thérapeutique d'IL2 à faibles doses dans la sclérose en plaques....

Membranous nephropathy induced by enzyme replacement therapy (ERT)

A new cause of membranous nephropathy, a renal disease induced by formation of immune deposits in the renal glomerulus, has been identified in a child...

Specialized consultations

​Specialized consultations have been established within i2B in order to accele​rate patient access to various specialists in the consor...